Commonwealth Equity Services LLC grew its holdings in shares of Petmed Express Inc (NASDAQ:PETS) by 27.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,963 shares of the company’s stock after buying an additional 2,350 shares during the period. Commonwealth Equity Services LLC owned 0.05% of Petmed Express worth $390,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also made changes to their positions in the company. Parametric Portfolio Associates LLC boosted its holdings in shares of Petmed Express by 12.8% in the first quarter. Parametric Portfolio Associates LLC now owns 85,713 shares of the company’s stock valued at $2,467,000 after acquiring an additional 9,732 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Petmed Express by 449.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 350,478 shares of the company’s stock valued at $12,490,000 after purchasing an additional 286,660 shares in the last quarter. Dupont Capital Management Corp acquired a new position in shares of Petmed Express during the 2nd quarter valued at $236,000. Advisory Services Network LLC increased its position in shares of Petmed Express by 4,041.8% during the 2nd quarter. Advisory Services Network LLC now owns 16,567 shares of the company’s stock valued at $590,000 after purchasing an additional 16,167 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Petmed Express by 41.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,247 shares of the company’s stock worth $65,000 after buying an additional 656 shares in the last quarter. Institutional investors own 92.75% of the company’s stock.
In other news, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $41.00, for a total value of $1,230,000.00. Following the completion of the sale, the chief executive officer now owns 360,000 shares of the company’s stock, valued at $14,760,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.60% of the stock is owned by corporate insiders.
PETS has been the topic of a number of research analyst reports. BidaskClub lowered Petmed Express from a “hold” rating to a “sell” rating in a report on Wednesday. Sidoti upgraded shares of Petmed Express from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $37.00 to $41.00 in a report on Wednesday, August 19th. Finally, ValuEngine upgraded shares of Petmed Express from a “strong sell” rating to a “sell” rating in a report on Monday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the stock. Petmed Express currently has an average rating of “Hold” and a consensus price target of $30.50.
NASDAQ PETS opened at $29.17 on Wednesday. Petmed Express Inc has a 1 year low of $16.91 and a 1 year high of $42.88. The company has a market cap of $591.33 million, a PE ratio of 20.69 and a beta of 0.68. The stock’s 50-day moving average price is $32.14 and its two-hundred day moving average price is $32.66.
Petmed Express (NASDAQ:PETS) last released its earnings results on Monday, July 20th. The company reported $0.39 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.01). Petmed Express had a return on equity of 21.91% and a net margin of 9.41%. The firm had revenue of $96.20 million during the quarter, compared to analysts’ expectations of $90.96 million. During the same period last year, the business earned $0.26 earnings per share. The business’s revenue was up 20.3% on a year-over-year basis.
Petmed Express Company Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.